Deepinder Goyal’s Temple plans pre-orders for limited-edition brain-health wearable

Temple, Deepinder Goyal’s health-wearable venture, is preparing pre-orders for a smaller limited launch edition of its cerebral blood-flow tracking device. The wearable is expected to cost ₹75,000–80,000, with initial shipments targeted before the end of 2026.

— Source published Fri, 21 Aug, 2026, 19:23 IST · First seen Fri, 21 Aug, 2026, 19:25 IST · Source Outlook Business

What happened

Deepinder Goyal’s health-wearable venture Temple will soon open pre-orders for a smaller limited launch edition, with deliveries targeted by end-2026. The

Key facts

  • Temple is less than half the size of its earlier version
  • Expected price: ₹75,000–80,000
  • Expected next funding valuation: around $500 million
  • ESOP buyback valuation: $375 million
  • Raised $54 million in February at a $190 million valuation
  • More than 80 individual investors

Why this matters

Temple’s move toward commercialization makes it a potential partnership target for premium wellness retailers, diagnostic networks and consumer-health platforms seeking differentiated brain-health offerings.

What to watch

  • Preorder pricing, deposit size, refund terms and stated production volume.
  • Whether Temple discloses clinical-study results, peer-reviewed evidence or regulatory status.
  • Language used in marketing: cerebral blood-flow monitoring, brain-health guidance, performance optimization or disease-related claims.
  • Initial shipment timing versus the before-end-2026 target.
  • Partnership announcements with hospitals, clinics, insurers, researchers or enterprise wellness buyers.
  • Evidence of a recurring subscription or paid analytics layer.
  • Customer feedback on comfort, battery life, actionable insight quality and data privacy.
  • Open a controlled preorder/waitlist program with refundable deposits, eligibility screening and explicit shipment windows.
  • Use limited-edition design, founder access and scarcity messaging to position the product as luxury preventive-health technology rather than a fitness tracker.
  • Publish technical validation, accuracy methodology, contraindications and a clear boundary between wellness insights and medical diagnosis.
  • Build partnerships with neurologists, longevity clinics, diagnostic centers and corporate executive-health programs.
  • Test subscription tiers for interpretation, longitudinal reports, coaching and clinician-reviewed insights.
  • Prioritize concierge onboarding and post-purchase support to reduce returns and protect brand trust at the premium price point.